A Phase 2 interventional study of Isomyosamine 250mg and Placebo 250 mg in Sarcopenia in Elderly, Frailty and Frailty/Sarcopenia, sponsored by TNF Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-24.
Sponsored by TNF Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.
This study's planned enrollment of 60 is below the median of 82 across 769 interventional studies indexed under Frailty.
Browse Frailty studies →TNF Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential subjects' intention to avoid reproductive activity will be confirmed
And one or more of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomly assigned to receive 1000 mg Isomyosamine daily via four 250 mg capsules
Drug: Isomyosamine 250mg
Subjects randomly assigned to receive 1000 mg placebo daily via four 250 mg capsules
Drug: Placebo 250 mg
Isomyosamine 250 mg capsules dosed 4 times daily
Placebo 250 mg capsule 4 times daily
Change in Short Physical Performance Battery (SPPB) Test in subjects treated with Isomyosamine or placebo
Time frame: From enrollment to the end of treatment at 90 days
4-meter walk test
Change in the time taken to walk 4 meters through 90 days dosing.
Time frame: From enrollment to the end of treatment at 90 days
6-minute walk test
Change in the distance walked in the 6-minute walk test (m) through 90 days dosing.
Time frame: From enrollment to the end of treatment at 90 days
Grip strength
Change in grip strength score over 90 day dosing.
Time frame: From enrollment to the end of treatment at 90 days
Effect on serum levels of biochemical markers of TNF activation
Time frame: From enrollment to the end of treatment at 90 days
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in the Isomyosamine vs Placebo groups
Time frame: From enrollment to the end of treatment at 90 days
No study locations are listed for this record.
Plan to share: No
Start is estimated for May 2025; primary completion for Mar 2026, 10 months later.
Of 20 phase 2 interventional studies under Frailty, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 94. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TNF Pharmaceuticals, Inc.